These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10845268)

  • 41. [Cost of illness in Parkinson disease. A retrospective 3-month analysis of direct costs].
    Dodel RC; Singer M; Köhne-Volland R; Selzer R; Scholz W; Rathay B; Oertel WH
    Nervenarzt; 1997 Dec; 68(12):978-84. PubMed ID: 9465341
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The cost effectiveness of hepatitis immunization for US college students.
    Jacobs RJ; Saab S; Meyerhoff AS
    J Am Coll Health; 2003 May; 51(6):227-36. PubMed ID: 14510025
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Juvenile obesity and comorbidity type 2 diabetes mellitus (T2 DM) in Germany: development and cost-of-illness analysis].
    Wolfenstetter SB
    Gesundheitswesen; 2006 Oct; 68(10):600-12. PubMed ID: 17099820
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.
    Kuan RK; Janssen R; Heyward W; Bennett S; Nordyke R
    Vaccine; 2013 Aug; 31(37):4024-32. PubMed ID: 23707166
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatitis B virus exposure and vaccination in a cohort of people who inject drugs: what has been the impact of targeted free vaccination?
    Winter RJ; Dietze PM; Gouillou M; Hellard ME; Robinson P; Aitken CK
    J Gastroenterol Hepatol; 2013 Feb; 28(2):314-22. PubMed ID: 23190264
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Economic evaluation of universal newborn hepatitis B vaccination in China.
    Lu SQ; McGhee SM; Xie X; Cheng J; Fielding R
    Vaccine; 2013 Apr; 31(14):1864-9. PubMed ID: 23384752
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal.
    Dusheiko GM; Roberts JA
    Hepatology; 1995 Dec; 22(6):1863-73. PubMed ID: 7489999
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Socioeconomic relevance of acute exacerbations of chronic bronchitis in the Federal Republic of Germany. A prospective cost of illness study].
    Rychlik R; Pfeil T; Daniel D; Pfeil B; Mast O; Thate-Waschke I; Lorenz J
    Dtsch Med Wochenschr; 2001 Mar; 126(13):353-9. PubMed ID: 11332229
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Surveillance for acute viral hepatitis - United States, 2007.
    Daniels D; Grytdal S; Wasley A;
    MMWR Surveill Summ; 2009 May; 58(3):1-27. PubMed ID: 19478727
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain.
    Idris BI; Brosa M; Richardus JH; Esteban R; Schalm SW; Buti M
    Eur J Gastroenterol Hepatol; 2008 Apr; 20(4):320-6. PubMed ID: 18334876
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of the duplicate notifiable reporting of hepatitis B infection in Zhejiang province, China, 2005-2015.
    He H; Zhou Y; Xie S
    Vaccine; 2017 Aug; 35(36):4702-4706. PubMed ID: 28750855
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epidemiology and economic importance of hepatitis B in the Federal Republic of Germany.
    Lange W; Masihi KN
    Postgrad Med J; 1987; 63 Suppl 2(741):21-6. PubMed ID: 3684845
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeted outreach hepatitis B vaccination program in high-risk adults: The fundamental challenge of the last mile.
    Mangen MJ; Stibbe H; Urbanus A; Siedenburg EC; Waldhober Q; de Wit GA; van Steenbergen JE;
    Vaccine; 2017 May; 35(24):3215-3221. PubMed ID: 28483198
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [A cost analysis of diagnostic screening for the differentiation of type-1 and type-2 diabetics aged 30 to 45. A health economics modelling calculation].
    Kilburg A; Bruchhausen Y; Thomas J; Rychlik R
    Dtsch Med Wochenschr; 1999 Dec; 124(50):1510-7. PubMed ID: 10633777
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model.
    Aggarwal R; Ghoshal UC; Naik SR
    J Hepatol; 2003 Feb; 38(2):215-22. PubMed ID: 12547411
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost of Illness of Chronic Hepatitis B Infection in Vietnam.
    Tu HAT; Woerdenbag HJ; Riewpaiboon A; Kane S; Le DM; Postma MJ; Li SC
    Value Health Reg Issues; 2012 May; 1(1):23-28. PubMed ID: 29702821
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa.
    Mokaya J; Burn EAO; Tamandjou CR; Goedhals D; Barnes EJ; Andersson M; Pinedo-Villanueva R; Matthews PC
    BMC Public Health; 2019 Jun; 19(1):829. PubMed ID: 31242901
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Study on the cost-effectiveness, benefit and utility analysis on the infant inoculation hepatitis B vaccine in Shanghai].
    Wu GY; Gong YL; Yu SL; Shao RT; Qin HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):474-8. PubMed ID: 15231120
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis.
    Fabrizi F; Di Filippo S; Marcelli D; Guarnori I; Raffaele L; Crepaldi M; Erba G; Locatelli F
    Nephron; 1996; 72(4):536-43. PubMed ID: 8730417
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An economic analysis of adult hepatitis B vaccination in China.
    Zheng H; Wang FZ; Zhang GM; Cui FQ; Wu ZH; Miao N; Sun XJ; Liang XF; Li L
    Vaccine; 2015 Nov; 33(48):6831-9. PubMed ID: 26384449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.